



POWER OF ATTORNEY FROM ASSIGNEE

29,021

August

Human Genome Sciences, Inc., a corporation of Delaware, having a principal place of business at 9410 Key West Avenue, Rockville, MD 20850, is assignee of the entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), by reason of an Assignment to the Assignee executed on 1) May 10, 2002 ; 2) May 17, 2002 ; 3) ~~April 2, 2002~~ ; 4) May 28, 2002 ; 5) May 23, 2002 ; 6) May 20, 2002 ; 7) August 31, 2002 ; 8) May 20, 2002 ; 9) May 19, 2002 ; 9) XXXXXXXXXXXXXXXX ; 10) September 25, 2002 ; 11) October 9, 2002 ; 12) May 29, 2002 of an invention known as Keratinocyte Growth Factor-2 (Attorney Docket No. 1488.036000O/EKS/AJK), which is disclosed and claimed in a patent application of the same title by the inventor(s) 1) Steven M. RUBEN; 2) Pablo JIMENEZ; 3) Roxanne D. DUAN; 4) Mark A. RAMPY; 5) Donna MENDRICK; 6) Jun ZHANG; 7) Jian NI; 8) Paul A. MOORE; 9) Timothy A. COLEMAN; 10) Joachim R. GRUBER; 11) Patrick J. DILLON; 12) Reiner L. GENTZ (said application filed on January 4, 2002 at the U.S. Patent and Trademark Office, having Application Number 10/035,212).

The Assignee hereby appoint the U.S. attorneys/agents associate with **CUSTOMER NUMBER 28393** to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith, such attorneys currently being: James H. Davis, Registration No. 40,582; Kenley K. Hoover, Registration No. 40,302; Michele M. Wales, Registration No. 43,975; Mark J. Hyman, Registration No. 46,789; and Janet M. Martineau, Registration No. 46,903, all of Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, and Robert Greene Sterne, Esq., Reg. No. 28,912; Edward J. Kessler, Esq., Reg. No. 25,688; Jorge A. Goldstein, Esq., Reg. No. 29,021; David K.S. Cornwell, Esq., Reg. No. 31,944; Robert W. Esmond, Esq., Reg. No. 32,893; Tracy-Gene G. Durkin, Esq., Reg. No. 32,831; Michele A. Cimbala, Esq., Reg. No. 33,851; Michael B. Ray, Esq., Reg. No. 33,997; Robert E. Sokohl, Esq., Reg. No. 36,013; Eric K. Steffe, Esq., Reg. No. 36,688; Michael Q. Lee, Esq., Reg. No. 35,239; Steven R. Ludwig, Esq., Reg. No. 36,203; John M. Covert, Esq., Reg. No. 38,759; Linda E. Alcorn, Esq., Reg. No. 39,588; Lawrence B. Bugaisky, Esq., Reg. No. 35,086; Donald J. Featherstone, Esq., Reg. No. 33,876; and Robert C. Millonig, Esq., Reg. No. 34,395. The Assignee hereby grants said attorneys/agents the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

Send correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
U.S.A.

Direct phone calls to 202-371-2600.

FOR: Human Genome Sciences, Inc.

SIGNATURE: *JH Davis*

BY: James H. Davis

TITLE: Senior Vice President and General Counsel

DATE: October 17, 2002



Certificate Under 37 C.F.R. § 3.73(b)

Applicant/Patent Owner: 1) Steven M. RUBEN; 2) Pablo JIMENEZ; 3) Roxanne D. DUAN; 4) Mark A. RAMPY; 5) Donna MENDRICK; 6) Jun ZHANG; 7) Jian NI; 8) Paul A. MOORE; 9) Timothy A. COLEMAN; 10) Joachim R. GRUBER; 11) Patrick J. DILLON; 12) Reiner L. GENTZ

Application No./Patent No.: 10/035,212 Filed/Issue Date: January 4, 2002

Entitled: Keratinocyte Growth Factor-2

Human Genome Sciences, Inc.

(Name of Assignee)

, a Corporation

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest, or
2. ☐ an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

- A. ☒ An Assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s) of the patent application/patent identified above to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302-302.8]

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

Date: October 17, 2002

Name: James H. Davis

Title: Senior Vice President and General Counsel

Signature: _____

**DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION**

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: 1) Steven M. RUBEN; 2) Pablo JIMENEZ; 3) Roxanne D. DUAN; 4) Mark A. RAMPY; 5) Donna MENDRICK; 6) Jun ZHANG; 7) Jian NI; 8) Paul A. MOORE; 9) Timothy A. COLEMAN; 10) Joachim R. GRUBER; 11) Patrick J. DILLON; 12) Reiner L. GENTZ the undersigned inventor(s) hereby sell(s) and assign(s) to Human Genome Sciences, Inc. (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es)

☒ for the United States of America (as defined in 35 U.S.C. § 100),

☒ and throughout the world,

(a) in the invention(s) known as Keratinocyte Growth Factor-2 for which application(s) for patent in the United States of America has (have) been executed by the undersigned on 1) _____ : 2) _____ : 3) _____
4) _____ : 5) _____ : 6) _____ : 7) 8/31/02 :
8) _____ : 9) _____ : 10) _____ :
11) _____ : 12) _____ (also known as United States Application No. 10/035,212, filed January 4, 2002), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with the application(s) and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventor(s) hereby represent(s) that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventor(s) hereby grant(s) James H. Davis, Registration No. 40,582; Kenley K. Hoover, Registration No. 40,302; Michele M. Wales, Registration No. 43,975; Mark J. Hyman, Registration No. 46,789; and Janet M. Martineau, Registration No. 46,903, all of Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, and Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Estlund, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,331; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; John M. Covert, Esquire, Registration No. 38,759; Linda E. Alcorn, Esquire, Registration No. 39,588; Lawrence B. Bugaisky, Esquire, Registration No. 35,086; Donald J. Featherstone, Esquire, Registration No. 33,876; and Robert C. Millionig, Esquire, Registration No. 34,395, all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventor(s) on the date opposite his/her name.

Date: _____ Signature of Inventor: Steven M. RUBEN

Date: _____ Signature of Inventor: Pablo JIMENEZ

Date: _____ Signature of Inventor: Roxanne D. DUAN

Date: _____ Signature of Inventor: Mark A. RAMPY

Date: _____ Signature of Inventor: Donna MENDRICK

Date: _____ Signature of Inventor: _____
Jun ZHANG

Date: 8/31/02 Signature of Inventor: _____
Jian NI

Date: _____ Signature of Inventor: _____
Paul A. MOORE

Date: _____ Signature of Inventor: _____
Timothy A. COLEMAN

Date: _____ Signature of Inventor: _____
Joachim R. GRUBER

Date: _____ Signature of Inventor: _____
Patrick J. DILLON

Date: _____ Signature of Inventor: _____
Reiner L. GENTZ

**DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION**

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: 1) Steven M. RUBEN; 2) Pablo JIMENEZ; 3) Roxanne D. DUAN; 4) Mark A. RAMPY; 5) Donna MENDRICK; 6) Jun ZHANG; 7) Jian NI; 8) Paul A. MOORE; 9) Timothy A. COLEMAN; 10) Joachim R. GRUBER; 11) Patrick J. DILLON; 12) Reiner L. GENTZ the undersigned inventor(s) hereby sell(s) and assign(s) to Human Genome Sciences, Inc. (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es) ☒ for the United States of America (as defined in 35 U.S.C. § 100),
☒ and throughout the world,

(a) in the invention(s) known as Keratinocyte Growth Factor-2 for which application(s) for patent in the United States of America has (have) been executed by the undersigned on 1) 5/10/02 ; 2) _____ ; 3) _____ ;
4) 5/28/02 ; 5) _____ ; 6) 5/20/02 ; 7) _____ ;
8) 5/20/02 ; 9) _____ ; 9) _____ ; 10) _____ ;
11) _____ ; 12) 5/29/02 (also known as United States Application No. 10/035,212, filed January 4, 2002), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.


The undersigned inventor(s) agree(s) to execute all papers necessary in connection with the application(s) and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventor(s) hereby represent(s) that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.


The undersigned inventor(s) hereby grant(s) James H. Davis, Registration No. 40,582; Kenley K. Hoover, Registration No. 40,302; Michele M. Wales, Registration No. 43,975; Mark J. Hyman, Registration No. 46,789; and Janet M. Martineau, Registration No. 46,903, all of Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, and Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; John M. Covert, Esquire, Registration No. 38,759; Linda E. Alcorn, Esquire, Registration No. 39,588; Lawrence B. Bugaisky, Esquire, Registration No. 35,086; Donald J. Featherstone, Esquire, Registration No. 33,876; and Robert C. Millonig, Esquire, Registration No. 34,395, all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventor(s) on the date opposite his/her name.


Date: 5/14/02 Signature of Inventor: 
Steven M. RUBEN

Date: _____ Signature of Inventor: _____
Pablo JIMENEZ


Date: _____ Signature of Inventor: _____
Roxanne D. DUAN

Date: 28 May 2002 Signature of Inventor: 
Mark A. RAMPY

Date: _____ Signature of Inventor: _____
Donna MENDRICK

Date: 5/20/02 Signature of Inventor: 
Jun ZHANG


Date: _____ Signature of Inventor: _____
Jian NI

Date: 5/20/02 Signature of Inventor: 
Paul A. MOORE

Date: _____ Signature of Inventor: _____
Timothy A. COLEMAN

Date: _____ Signature of Inventor: _____
Joachim R. GRUBER

Date: _____ Signature of Inventor: _____
Patrick J. DILLON

Date: 5/29/02 Signature of Inventor: 
Reiner L. GENTZ

DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: 1) Steven M. RUBEN; 2) Pablo JIMENEZ; 3) Roxanne D. DUAN; 4) Mark A. RAMPY; 5) Donna MENDRICK; 6) Jun ZHANG; 7) Jian NI; 8) Paul A. MOORE; 9) Timothy A. COLEMAN; 10) Joachim R. GRUBER; 11) Patrick J. DILLON; 12) Reiner L. GENTZ the undersigned inventor(s) hereby sell(s) and assign(s) to Human Genome Sciences, Inc. (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es) ☒ for the United States of America (as defined in 35 U.S.C. § 100),
☒ and throughout the world,

29,021
(a) in the invention(s) known as Keratinocyte Growth Factor-2 for which application(s) for patent in the United States of America has (have) been executed by the undersigned on 1) _____ ; 2) _____ ; 3) _____ ;
4) _____ ; 5) 5/23/02 ; 6) _____ ; 7) _____ ;
8) _____ ; 9) _____ ; 10) _____ ;
11) _____ ; 12) _____ (also known as United States Application No. 10/035,212, filed January 4, 2002), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with the application(s) and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventor(s) hereby represent(s) that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventor(s) hereby grant(s) James H. Davis, Registration No. 40,582; Kenley K. Hoover, Registration No. 40,302; Michele M. Wales, Registration No. 43,975; Mark J. Hyman, Registration No. 46,789; and Janet M. Martineau, Registration No. 46,903, all of Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, and Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; John M. Covert, Esquire, Registration No. 38,759; Linda E. Alcorn, Esquire, Registration No. 39,588; Lawrence B. Bugaisky, Esquire, Registration No. 35,086; Donald J. Featherstone, Esquire, Registration No. 33,876; and Robert C. Millonig, Esquire, Registration No. 34,395, all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.


IN WITNESS WHEREOF, executed by the undersigned inventor(s) on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
Steven M. RUBEN

Date: _____ Signature of Inventor: _____
Pablo JIMENEZ

Date: _____ Signature of Inventor: _____
Roxanne D. DUAN

Date: _____ Signature of Inventor: _____
Mark A. RAMPY

Date: May 23, 2002 Signature of Inventor: 
Donna MENDRICK

Date: _____ Signature of Inventor: Jun ZHANG

Date: _____ Signature of Inventor: Jian NI

Date: _____ Signature of Inventor: Paul A. MOORE

Date: _____ Signature of Inventor: Timothy A. COLEMAN

Date: _____ Signature of Inventor: Joachim R. GRUBER

Date: _____ Signature of Inventor: Patrick J. DILLON

Date: _____ Signature of Inventor: Reiner L. GENTZ

DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: 1) Steven M. RUBEN; 2) Pablo JIMENEZ; 3) Roxanne D. DUAN; 4) Mark A. RAMPY; 5) Donna MENDRICK; 6) Jun ZHANG; 7) Jian NI; 8) Paul A. MOORE; 9) Timothy A. COLEMAN; 10) Joachim R. GRUBER; 11) Patrick J. DILLON; 12) Reiner L. GENTZ the undersigned inventor(s) hereby sell(s) and assign(s) to Human Genome Sciences, Inc. (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es) ☒ for the United States of America (as defined in 35 U.S.C. § 100),
☒ and throughout the world,

29021
(a) in the invention(s) known as Keratinocyte Growth Factor-2 for which application(s) for patent in the United States of America has (have) been executed by the undersigned on 1) _____ ; 2) _____ ; 3) 8/20/02 ; 4) _____ ; 5) _____ ; 6) _____ ; 7) _____ ; 8) _____ ; 9) _____ ; 9) _____ ; 10) _____ ; 11) _____ ; 12) _____ (also known as United States Application No. 10/035,212, filed January 4, 2002), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with the application(s) and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventor(s) hereby represent(s) that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventor(s) hereby grant(s) James H. Davis, Registration No. 40,582; Kenley K. Hoover, Registration No. 40,302; Michele M. Wales, Registration No. 43,975; Mark J. Hyman, Registration No. 46,789; and Janet M. Martineau, Registration No. 46,903, all of Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, and Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; John M. Covert, Esquire, Registration No. 38,759; Linda E. Alcorn, Esquire, Registration No. 39,588; Lawrence B. Bugaisky, Esquire, Registration No. 35,086; Donald J. Featherstone, Esquire, Registration No. 33,876; and Robert C. Millonig, Esquire, Registration No. 34,395, all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventor(s) on the date opposite his/her name.

Date: _____ Signature of Inventor: Steven M. RUBEN

Date: _____ Signature of Inventor: Pablo JIMENEZ

Date: _____ Signature of Inventor: Roxanne Duan 8/26/00
Roxanne D. DUAN

Date: _____ Signature of Inventor: Mark A. RAMPY

Date: _____ Signature of Inventor: Donna MENDRICK

Date: _____ Signature of Inventor: Jun ZHANG

Date: _____ Signature of Inventor: Jian NI

Date: _____ Signature of Inventor: Paul A. MOORE

Date: _____ Signature of Inventor: Timothy A. COLEMAN

Date: _____ Signature of Inventor: Joachim R. GRUBER

Date: _____ Signature of Inventor: Patrick J. DILLON

Date: _____ Signature of Inventor: Reiner L. GENTZ

**DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION**

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: 1) Steven M. RUBEN; 2) Pablo JIMENEZ; 3) Roxanne D. DUAN; 4) Mark A. RAMPY; 5) Donna MENDRICK; 6) Jun ZHANG; 7) Jian NI; 8) Paul A. MOORE; 9) Timothy A. COLEMAN; 10) Joachim R. GRUBER; 11) Patrick J. DILLON; 12) Reiner L. GENTZ the undersigned inventor(s) hereby sell(s) and assign(s) to Human Genome Sciences, Inc. (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es) ☒ for the United States of America (as defined in 35 U.S.C. § 100),
☒ and throughout the world,

29,021
(a) in the invention(s) known as Keratinocyte Growth Factor-2 for which application(s) for patent in the United States of America has (have) been executed by the undersigned on 1) _____ ; 2) _____ ; 3) _____ ;
4) _____ ; 5) _____ ; 6) _____ ; 7) _____ ;
8) _____ ; 9) _____ ; 9) 5/19/02 ; 10) _____ ;
11) _____ ; 12) _____ (also known as United States Application No. 10/035,212, filed January 4, 2002), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with the application(s) and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventor(s) hereby represent(s) that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventor(s) hereby grant(s) James H. Davis, Registration No. 40,582; Kenley K. Hoover, Registration No. 40,302; Michele M. Wales, Registration No. 43,975; Mark J. Hyman, Registration No. 46,789; and Janet M. Martineau, Registration No. 46,903, all of Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, and Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; John M. Covert, Esquire, Registration No. 38,759; Linda E. Alcorn, Esquire, Registration No. 39,588; Lawrence B. Bugaisky, Esquire, Registration No. 35,086; Donald J. Featherstone, Esquire, Registration No. 33,876; and Robert C. Millonig, Esquire, Registration No. 34,395, all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventor(s) on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
Steven M. RUBEN

Date: _____ Signature of Inventor: _____
Pablo JIMENEZ

Date: _____ Signature of Inventor: _____
Roxanne D. DUAN


Date: _____ Signature of Inventor: _____
Mark A. RAMPY

Date: _____ Signature of Inventor: _____
Donna MENDRICK

Date: _____ Signature of Inventor: _____
Jun ZHANG

Date: _____ Signature of Inventor: _____
Jian NI

Date: _____ Signature of Inventor: _____
Paul A. MOORE

Date: 5/19/02 Signature of Inventor: 
Timothy A. COLEMAN

Date: _____ Signature of Inventor: _____
Joachim R. GRUBER

Date: _____ Signature of Inventor: _____
Patrick J. DILLON

Date: _____ Signature of Inventor: _____
Reiner L. GENTZ

**DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION**

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: 1) Steven M. RUBEN; 2) Pablo JIMENEZ; 3) Roxanne D. DUAN; 4) Mark A. RAMPY; 5) Donna MENDRICK; 6) Jun ZHANG; 7) Jian NI; 8) Paul A. MOORE; 9) Timothy A. COLEMAN; 10) Joachim R. GRUBER; 11) Patrick J. DILLON; 12) Reiner L. GENTZ the undersigned inventor(s) hereby sell(s) and assign(s) to Human Genome Sciences, Inc. (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es) ☒ for the United States of America (as defined in 35 U.S.C. § 100),
☒ and throughout the world,

29,021
*
(a) in the invention(s) known as Keratinocyte Growth Factor-2 for which application(s) for patent in the United States of America has (have) been executed by the undersigned on 1) _____ ; 2) 5/17/02 ; 3) _____ ;
4) _____ ; 5) _____ ; 6) _____ ; 7) _____ ;
8) _____ ; 9) _____ ; 9) _____ ; 10) _____ ;
11) _____ ; 12) _____ (also known as United States Application No. 10/035,212, filed January 4, 2002), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with the application(s) and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventor(s) hereby represent(s) that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventor(s) hereby grant(s) James H. Davis, Registration No. 40,582; Kenley K. Hoover, Registration No. 40,302; Michele M. Wales, Registration No. 43,975; Mark J. Hyman, Registration No. 46,789; and Janet M. Martineau, Registration No. 46,903, all of Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, and Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; John M. Covert, Esquire, Registration No. 38,759; Linda E. Alcorn, Esquire, Registration No. 39,588; Lawrence B. Bugaisky, Esquire, Registration No. 35,086; Donald J. Featherstone, Esquire, Registration No. 33,876; and Robert C. Millonig, Esquire, Registration No. 34,395, all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventor(s) on the date opposite his/her name.

Date: _____ Signature of Inventor: _____

Steven M. RUBEN

Date: _____ Signature of Inventor: _____

Pablo JIMENEZ

Date: _____ Signature of Inventor: _____

Roxanne D. DUAN

Date: _____ Signature of Inventor: _____

Mark A. RAMPY

Date: _____ Signature of Inventor: _____

Donna MENDRICK

Date: _____ Signature of Inventor: Jun ZHANG

Date: _____ Signature of Inventor: Jian NI

Date: _____ Signature of Inventor: Paul A. MOORE

Date: _____ Signature of Inventor: Timothy A. COLEMAN

Date: _____ Signature of Inventor: Joachim R. GRUBER

Date: _____ Signature of Inventor: Patrick J. DILLON

Date: _____ Signature of Inventor: Reiner L. GENTZ

**DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION**

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: 1) Steven M. RUBEN; 2) Pablo JIMENEZ; 3) Roxanne D. DUAN; 4) Mark A. RAMPY; 5) Donna MENDRICK; 6) Jun ZHANG; 7) Jian NI; 8) Paul A. MOORE; 9) Timothy A. COLEMAN; 10) Joachim R. GRUBER; 11) Patrick J. DILLON; 12) Reiner L. GENTZ the undersigned inventor(s) hereby sell(s) and assign(s) to Human Genome Sciences, Inc. (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es) ☒ for the United States of America (as defined in 35 U.S.C. § 100),
☒ and throughout the world,

(a) in the invention(s) known as Keratinocyte Growth Factor-2 for which application(s) for patent in the United States of America has (have) been executed by the undersigned on 1) ; 2) ; 3) ; 4) ; 5) ; 6) ; 7) ; 8) ; 9) ; 9) ; 10) ; 11) 10/9/02 ; 12) (also known as United States Application No. 10/035,212, filed January 4, 2002), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with the application(s) and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventor(s) hereby represent(s) that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventor(s) hereby grant(s) James H. Davis, Registration No. 40,582; Kenley K. Hoover, Registration No. 40,302; Michele M. Wales, Registration No. 43,975; Mark J. Hyman, Registration No. 46,789; and Janet M. Martineau, Registration No. 46,903, all of Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, and Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; John M. Covert, Esquire, Registration No. 38,759; Linda E. Alcorn, Esquire, Registration No. 39,588; Lawrence B. Bugaisky, Esquire, Registration No. 35,086; Donald J. Featherstone, Esquire, Registration No. 33,876; and Robert C. Millonig, Esquire, Registration No. 34,395, all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventor(s) on the date opposite his/her name.

Date: _____ Signature of Inventor: Steven M. RUBEN

Date: _____ Signature of Inventor: Pablo JIMENEZ

Date: _____ Signature of Inventor: Roxanne D. DUAN

Date: _____ Signature of Inventor: Mark A. RAMPY

Date: _____ Signature of Inventor: Donna MENDRICK

Date: _____ Signature of Inventor: Jun ZHANG

Date: _____ Signature of Inventor: Jian NI

Date: _____ Signature of Inventor: Paul A. MOORE

Date: _____ Signature of Inventor: Timothy A. COLEMAN

Date: _____ Signature of Inventor: Joachim R. GRUBER

Date: 10.09.02 Signature of Inventor: Patrick J. DILLON

Date: _____ Signature of Inventor: Reiner L. GENTZ

**DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION**

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: 1) Steven M. RUBEN; 2) Pablo JIMENEZ; 3) Roxanne D. DUAN; 4) Mark A. RAMPY; 5) Donna MENDRICK; 6) Jun ZHANG; 7) Jian NI; 8) Paul A. MOORE; 9) Timothy A. COLEMAN; 10) Joachim R. GRUBER; 11) Patrick J. DILLON; 12) Reiner L. GENTZ the undersigned inventor(s) hereby sell(s) and assign(s) to Human Genome Sciences, Inc. (the Assignee) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es) ☒ for the United States of America (as defined in 35 U.S.C. § 100),
☒ and throughout the world,

(a) in the invention(s) known as Keratinocyte Growth Factor-2 for which application(s) for patent in the United States of America has (have) been executed by the undersigned on 1) _____ ; 2) _____ ; 3) _____ ;
4) _____ ; 5) _____ ; 6) _____ ; 7) _____ ;
8) _____ ; 9) _____ ; 9) _____ ; 10) 4/25/02 ;
11) _____ ; 12) _____ (also known as United States Application No. 10/035,212, filed January 4, 2002), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with the application(s) and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventor(s) hereby represent(s) that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

The undersigned inventor(s) hereby grant(s) James H. Davis, Registration No. 40,582; Kenley K. Hoover, Registration No. 40,302; Michele M. Wales, Registration No. 43,975; Mark J. Hyman, Registration No. 46,789; and Janet M. Martineau, Registration No. 46,903, all of Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850, and Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gené G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; John M. Covert, Esquire, Registration No. 38,759; Linda E. Alcorn, Esquire, Registration No. 39,588; Lawrence B. Bugaisky, Esquire, Registration No. 35,086; Donald J. Featherstone, Esquire, Registration No. 33,876; and Robert C. Millonig, Esquire, Registration No. 34,395, all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventor(s) on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
Steven M. RUBEN

Date: _____ Signature of Inventor: _____
Pablo JIMENEZ

Date: _____ Signature of Inventor: _____
Roxanne D. DUAN

Date: _____ Signature of Inventor: _____
Mark A. RAMPY

Date: _____ Signature of Inventor: _____
Donna MENDRICK

Date: _____ Signature of Inventor: Jun ZHANG

Date: _____ Signature of Inventor: Jian NI

Date: _____ Signature of Inventor: Paul A. MOORE

Date: _____ Signature of Inventor: Timothy A. COLEMAN

Date: 9/25/02 Signature of Inventor: Joachim R. GRUBER

Date: _____ Signature of Inventor: Patrick J. DILLON

Date: _____ Signature of Inventor: Reiner L. GENTZ